Drug makers to vie for big pies over Plavix market

Published: 2008-01-23 06:59:00

Updated: 2008-01-23 06:59:00

The country's generic makers will be in a fierce race to snatch up a bigger market share of Plavix (clopidogrel bisulfate) as the patent court has upheld that Korean makers' generic clopidogrel bisulfate does not infringes on Sanofi-Aventis's patent.

Chong Kun Dang and other drug makers are in...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK